$BLLN

Sakakibara Shan Riku sold $786K of BLLN

Sakakibara Shan Riku (Chief Product Officer) sold 8,000 shares of BillionToOne, Inc. (BLLN) at an average of $98.22 ($96.45–$100.00, $0.79M total) across 2 trades on 2026-06-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sakakibara Shan Riku
Published Jun 11, 2026, 12:36 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 1:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BLLN
Neutral
high confidence
Mentioned
$BLLN
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The only new information is the size/date/price range of the CPO’s open-market sale and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider-sale filing; it can marginally influence sentiment but does not provide new fundamental drivers in the text.

03

What to watch

Traders may overreact to insider sales; without concurrent guidance, trial, or contract updates, the signal is typically weak.

Relevance 4/10Novelty 2/10Timing: Filed 2026-06-10 for a 2026-06-08 sale.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for BillionToOne, Inc.

Company-level read

Ticker impact

$BLLNNeutralHigh confidence
Context

SEC Form 4 shows BLLN CPO Sakakibara Shan Riku sold 8,000 shares (~$785.8K) via an open-market sale under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely short-lived unless accompanied by other company-specific news.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying operational/regulatory/financial catalyst in the text.

Market effects

No sector read-through; this is company-specific insider liquidity rather than a sector/regulatory development.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • BillionToOne, Inc.

    Company whose insider transaction is disclosed on SEC Form 4.

  • Sakakibara Shan Riku

    Chief Product Officer who sold shares.

Related articles

$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.